BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:ALXN1920 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of ALXN1920\, from ClinicalTrials.gov estima
 tes.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07157787-11163@assetmemo.bio
DTSTAMP:20261121T004112Z
DTSTART;VALUE=DATE:20270702
DTEND;VALUE=DATE:20270703
SUMMARY:ALXN1920: Phase 2 readout est. (NCT07157787)
DESCRIPTION:ALXN1920\, phase 2\, Primary Membranous Nephropathy.\nStudy: St
 udy of ALXN1920 in Adult Participants With Primary Membranous Nephropathy 
 (PMN)\nEstimated primary completion: 2 July 2027. This is a ClinicalTrials
 .gov estimate\, not a confirmed readout date\, and it can move.\nDrug page
 : https://assetmemo.bio/drug/alxn1920#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT07157787
URL:https://assetmemo.bio/drug/alxn1920#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
